EUVIMEDEUVIMED entdecken
CrossrefInfokarte

COMPARATIVE STUDY BETWEEN INTRALESIONAL INJECTION OF PLATELET RICH PLASMA AND INTRA LESIONAL TRIAMCINOLONE FOR THE TREATMENT OF ALOPECIA AREATA

Faheema Afsar khan, Majid Hussain, Bushra Muzaffar Khan, Saima Afsar, Mairah Shafique, Sami ul Haq, Nadia Akbar, Adeel Siddique

Journal of Ayub Medical College Abbottabad · 2022-09-28 · 34 (4) · 762-765

DOI: 10.55519/jamc-04-10933 ↗
AbstractBibliografische Angaben

Abstract

Background: Alopecia areata is an autoimmune disorder of patchy non scarring hair loss. Steroids, either Intralesional, e.g, triamcinolone or potent topical, e.g, clobetasol are the first line treatment. Platelet rich plasma is an autologous concentrated plasma with growth factors which enhances regeneration of hair follicles. It is simple and effective treatment with no major side effects. Objective was to compare the efficacy of intralesional injection of platelet rich plasma and triamcinolone in patients of alopecia areata. It was a randomized controlled trial (open-labelled), conducted at the Dermatology Department, Combined Military Hospital Abbottabad from 1st May to 31st December 2021. Methods: Sixty clinically diagnosed patients of alopecia areata of the scalp were enrolled in the study. They were divided into two groups, A and B. Random numbers table was used to allocate 30 patients into each group. Group A patients were given an intralesional injection of triamcinolone while intralesional platelet rich plasma was given to Group B. Both treatments were repeated at one-month intervals for four months. In the study, Chi-square tests were used to compare effectiveness. It was considered significant when the p-value turned out to be

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →